Elsevier

Neurotoxicology and Teratology

Volume 68, July–August 2018, Pages 84-90
Neurotoxicology and Teratology

Full length article
Prevalence and associated birth outcomes of co-use of Cannabis and tobacco cigarettes during pregnancy

https://doi.org/10.1016/j.ntt.2018.06.001Get rights and content

Highlights

  • Pregnant women co-use Cannabis and tobacco cigarettes at high rates.

  • Cannabis use rates were higher than tobacco use rates in our sample.

  • Smaller head circumference and birth defects were associated with maternal co-use.

  • Interventions addressing prenatal co-use and Cannabis use are warranted.

Abstract

Use of Cannabis and use of tobacco overlap, and co-use of Cannabis and tobacco has increased over the past decade among adults. The current study aims to document the prevalence and correlates of co-use of Cannabis and tobacco cigarettes among adult pregnant women utilizing secondary data from a larger study that compared and validated screeners for illicit and prescription drug use during pregnancy. Pregnant women (N = 500; 71% African American; 65% never married, average age of 28 years) were recruited from two urban University obstetric clinics between January and December 2017. Participants self-reported demographic, Cannabis, and tobacco cigarette use characteristics, and provided urine and hair samples for drug testing. Within two weeks after due date, research staff reviewed participants' electronic medical records to collect birth outcome data. Results showed that 9.0% reported co-use of Cannabis and tobacco, 12.1% reported Cannabis only use, 7.8% reported tobacco cigarette only use, and 71.1% reported no Cannabis or tobacco cigarette use in the past month. The birth outcomes to emerge as significant correlates of co-use of Cannabis and tobacco cigarettes were small head circumference, and the occurrence of birth defects, with the co-use group having the highest odds of a small head circumference [aOR: 5.7 (1.1–28.9)] and birth defects [aOR: 3.1 (1.2–8.3)] compared with other use groups. The Cannabis only group had 12 times higher odds of a stillbirth or miscarriage (aOR = 12.1). Screening and interventions to address concurrent Cannabis and tobacco use during pregnancy are needed, particularly among subpopulations with higher co-use rates. It is imperative to further explore and highlight the possible health implications of maternal co-use given the high prevalence rates found in this study sample.

Introduction

Cannabis is the most commonly used illicit drug globally and in the United States (World Health Organization (WHO), 2016), and rates of Cannabis use among US adults have risen significantly in the past 15 years (Hasin et al., 2015). In contrast, tobacco use has declined (WHO, 2015), although it remains one of the world's biggest public health threats, contributing to the deaths of approximately 7 million people each year (WHO, 2017). In the US general population, co-use of Cannabis and tobacco has increased significantly over the past decade (Schauer et al., 2015). Co-use of Cannabis and tobacco can refer to many different behavioral patterns, including use in the same episode, use within the same product (i.e., blunt or spliff smoking), or use within the same time-period (in the past month). Co-use of Cannabis and tobacco, relative to use of either Cannabis or tobacco alone, is associated with several concerning clinical correlates, including increased risk of Cannabis use disorder (CUD), exacerbation of mental health symptoms, and poorer cessation outcomes (Agrawal et al., 2012; Agrawal and Lynskey, 2009; Coleman-Cowger et al., 2017; Montgomery, 2015; Peters et al., 2012; Ramo et al., 2012). Preliminary evidence also suggests that co-use of Cannabis and tobacco may be associated with additive, or even multiplicative, adverse health consequences relative to tobacco use only (Coleman-Cowger et al., 2017; Peters et al., 2016).

With rates of co-use of marijuana and tobacco increasing significantly in the US, a critical question is how prevalent co-use is among vulnerable populations who may be especially susceptible to associated negative health implications, such as pregnant women. Among pregnant women in the 2005–2014 data from the US National Survey on Drug Use and Health, co-use of Cannabis and tobacco was significantly more prevalent than Cannabis only use (3.3% vs. 1.0%) but less common than tobacco only use (13.3%) (Coleman-Cowger et al., 2017). Co-use of Cannabis and tobacco was associated with being younger and Black or Hispanic, and having past month use of alcohol and other illicit drugs (Coleman-Cowger et al., 2017). In other studies, substance use during pregnancy is more common in women who are younger, less educated, single, unemployed (Havens et al., 2009), socioeconomically disadvantaged, have a partner who smokes (Giglia et al., 2007), or belong to a racial or ethnic minority group (El Marroun et al., 2008; Ko et al., 2015), as well as in multigravid women (i.e., women who have been pregnant more than once) and women with unplanned pregnancies (El Marroun et al., 2008). Although co-use of Cannabis and tobacco during pregnancy appears to be higher among certain subpopulations characterized by demographic characteristics and by behaviors associated with adverse health effects, research on co-use of Cannabis and tobacco among high risk populations of pregnant women is limited.

The negative health consequences of smoking tobacco during pregnancy are well-known (US Department of Health and Human Services (USDHHS), 2014) but the evidence base for the health consequences of smoking Cannabis during pregnancy is less robust (Gunn et al., 2016). Extant findings suggest links to reduced birth weight (though with smaller effects than those seen with tobacco use), increased risk of babies small for gestational age, increased risk of neonatal intensive care admission, poorer cognitive performance in adolescence, and maternal anemia (Gunn et al., 2016); however, the limitations of extant research are significant and include the small number of studies, small samples, underreporting of use, and inability to control for confounding effects of other substance use (Volkow et al., 2014). Two notable longitudinal studies of prenatal marijuana exposure (Fried and Makin, 1987; Richardson et al., 2002) found no association between Cannabis use during pregnancy and increased miscarriage rates, premature deliveries or any other complications, but did find differences in neonatal behaviors (i.e., increased tremors and startles and poorer habituation to visual stimuli) and neuropsychological outcomes at 10 years of age (i.e., effects on learning, memory, and impulsivity). Most studies on the effects of Cannabis use on birth outcomes did statistically control for tobacco smoking, showing the independent effects of Cannabis use on outcomes. To our knowledge, no studies have examined the unique research question of how tobacco and Cannabis interact synergistically to influence birth outcomes; i.e., does co-use of Cannabis and tobacco, relative to use of either one alone, compound adverse health consequences to the mother and developing fetus?

Existing studies on the health consequences of smoking Cannabis during pregnancy were initiated over 30 years ago. In the past two decades, 29 US states have implemented medicinal Cannabis laws and 8 states plus the District of Columbia have legalized adult recreational use of Cannabis. The impact of changing state and local policies legalizing Cannabis remains unclear, but there is some evidence that these policies contribute to greater Cannabis availability and the increasing perception that Cannabis use is harmless (Budney and Borodovsky, 2017; Schulenberg et al., 2017), both of which could lead to changing Cannabis use patterns among pregnant women. Because Cannabis and tobacco are so closely associated, changing Cannabis use patterns could have downstream effects on tobacco use patterns. Furthermore, exponential increases in tetrahydrocannabinol (THC) potency, the primary psychoactive constituent of Cannabis, over the past decade, combined with the fact that maternal tissues act as a reservoir for THC and other cannabinoids which results in prolonged fetal exposure, could make Cannabis difficult to quit during pregnancy (Budney and Borodovsky, 2017; Schulenberg et al., 2017). For all of these reasons, current research on the prevalence and associated birth outcomes of co-use of Cannabis and tobacco use is needed.

The purpose of this study is to: 1) describe the prevalence of co-use of Cannabis and tobacco cigarettes reported by a convenience sample of pregnant women presenting to two urban prenatal clinics; 2) outline correlates of co-use of Cannabis and tobacco cigarettes; and 3) compare birth outcomes between pregnant women who co-use Cannabis and tobacco cigarettes, who currently smoke tobacco cigarettes but do not use Cannabis, who currently use Cannabis but do not smoke tobacco cigarettes, and who do not currently use Cannabis or tobacco cigarettes.

Section snippets

Sample

This study's sample was recruited from two obstetric clinics in Maryland as part of a larger study to compare and validate screeners for illicit and prescription drug use during pregnancy. Pregnant women were enrolled in the study if they met the following criteria: 1) currently pregnant; 2) age 18 years or older; 3) able to speak and understand English sufficiently to provide informed consent; and 4) natural hair length at least 3 cm to allow for drug testing. Participants were compensated

Demographic characteristics

Table 1 outlines the demographic characteristics of the study participants. There were 500 participants enrolled into the study from two urban obstetrics clinics. Overall, the sample consisted primarily of African-American women (71.3%) who had never been married (65.3%), with an average age of 27.9 (SD = 5.2) years. Approximately 32% of the study sample reported having had a previous miscarriage or stillbirth. With regard to pregnancy intention, slightly over one-third of study participants

Discussion

There are several key findings from this study that highlight the importance of examining Cannabis and tobacco co-use during pregnancy. First, in this sample, the prevalence rate of Cannabis and tobacco cigarette co-use as well as the prevalence rate of Cannabis only use is higher than the prevalence of tobacco cigarette only use, which is notable given the focus on tobacco cessation in clinical practice. This cross-sectional finding of high Cannabis prevalence aligns with recent trend studies

Transparency document

Transparency document.

Acknowledgments

The research reported in this article is supported by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) grant under Award Number R01DA041328 (PI-Coleman-Cowger). The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health.

References (48)

  • L. Montgomery

    Marijuana and tobacco use and co-use among African Americans: results from the 2013, National Survey on Drug Use and Health

    Addict. Behav.

    (2015)
  • D.E. Ramo et al.

    Tobacco and marijuana use among adolescents and young adults: a systematic review of their co-use

    Clin. Psychol. Rev.

    (2012)
  • G.A. Richardson et al.

    Prenatal alcohol and marijuana exposure: effects on neuropsychological outcomes at 10 years

    Neurotoxicol. Teratol.

    (2002)
  • G.L. Schauer et al.

    Assessing the overlap between tobacco and marijuana: trends in patterns of co-use of tobacco and marijuana in adults from 2003–2012

    Addict. Behav.

    (2015)
  • A. Agrawal et al.

    The co-occurring use and misuse of Cannabis and tobacco: a review

    Addiction

    (2012)
  • American College of Obstetricians and Gynecologists

    Marijuana use during pregnancy and lactation. Committee Opinion No. 722

    Obstet. Gynecol.

    (2017)
  • J. Becker et al.

    Development of an integrative cessation program for co-smokers of cigarettes and Cannabis: demand analysis, program description, and acceptability

    Substance abuse treatment, prevention, and policy

    (2013)
  • J. Becker et al.

    Effectiveness of different web-based interventions to prepare co-smokers of cigarettes and Cannabis for double cessation: a three-arm randomized controlled trial

    J. Med. Internet Res.

    (2014)
  • Q.L. Brown et al.

    Trends in marijuana use among pregnant and nonpregnant reproductive-aged women, 2002–2014

    JAMA

    (2017)
  • M.S. Cepeda et al.

    Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders

    Am. J. Epidemiol.

    (2003)
  • I. Chasnoff et al.

    Validation of the 4P's plus© screen for substance use in pregnancy validation of the 4P's plus

    J. Perinatol.

    (2007)
  • V.H. Coleman-Cowger et al.

    Comparison and validation of screening tools for substance use in pregnancy: a cross-sectional study conducted in Maryland prenatal clinics

    BMJ Open

    (2018)
  • T.P. Dominguez

    Adverse birth outcomes in African American women: the social context of persistent reproductive disadvantage

    Soc. Work Public Health

    (2011)
  • D. English et al.

    Maternal Cannabis use and birth weight: a meta-analysis

    Addiction

    (1997)
  • Cited by (43)

    • Associations between prenatal and postnatal substance exposure and salivary C-reactive protein in early childhood

      2023, Neurotoxicology and Teratology
      Citation Excerpt :

      Research on co-exposure to tobacco and cannabis during pregnancy and infancy is a timely public health issue. Following recent legalization in numerous states, coupled with changes in societal attitudes, cannabis use during pregnancy has increased, as has co-use of cannabis and tobacco (Brown et al., 2017; Agrawal et al., 2019; Coleman-Cowger et al., 2018; Gnofam et al., 2020). Similarly, with the increase in new nicotine delivery systems (e.g., electronic cigarettes) as a replacement for combustible cigarettes, use of tobacco products are anticipated to increase as well, including among pregnant women (Wagner et al., 2017).

    • Pregnancy Loss

      2022, Physician Assistant Clinics
    View all citing articles on Scopus
    View full text